Literature DB >> 8032153

The alcohol dehydrogenase system.

H Jörnvall1.   

Abstract

Alcohol dehydrogenases constitute a complex system of enzymes, classes, isozymes, and allelic variants. The zinc containing, well-known liver enzyme is a class I medium-chain alcohol dehydrogenase. Other classes of this family include the class II protein, the glutathione-dependent formaldehyde dehydrogenase (the class III enzyme), the stomach-expressed class IV form, and the recently defined class V protein. Characterized forms suggest that the glutathione-dependent formaldehyde dehydrogenase is the original ancestor, defining a role for the whole protein family in cellular defense mechanisms. The isozyme-multiple class I protein is derived from an early gene duplication, allowing sub-specialization in vertebrates. Class IV is the one most ethanol-active and appears to be derived from the class I line. Allelic variants within class I, in association with aldehyde dehydrogenase variants, correlate with population differences in ethanol metabolism and hence with susceptibility to develop alcohol-related diseases. The structures also correlate with functional properties and define molecular building units for the whole family.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032153     DOI: 10.1007/978-3-0348-7330-7_22

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  3 in total

Review 1.  Allosteric modulation of ATP-gated P2X receptor channels.

Authors:  Claudio Coddou; Stanko S Stojilkovic; J Pablo Huidobro-Toro
Journal:  Rev Neurosci       Date:  2011-03-16       Impact factor: 4.353

Review 2.  Trace metals in the brain: allosteric modulators of ligand-gated receptor channels, the case of ATP-gated P2X receptors.

Authors:  J Pablo Huidobro-Toro; Ramón A Lorca; Claudio Coddou
Journal:  Eur Biophys J       Date:  2007-10-31       Impact factor: 1.733

Review 3.  New perspectives on evolutionary medicine: the relevance of microevolution for human health and disease.

Authors:  Frank Jakobus Rühli; Maciej Henneberg
Journal:  BMC Med       Date:  2013-04-29       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.